Summary: Consent Conditions G0362-01 issued to Applied Genetics Technologies Corporation, USA, to carry out a clinical trial on patients suffering from alpha-1 antitrypsin deficiency, using a Genetically Modified Micro-Organism (GMM). This trial did not proceed.
